Current severe psoriasis and the Rule of Tens

British Journal of Dermatology

Volumn 152, Issue 5, 2005, Pages 861-867

  Finlay, Andrew Y ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Dermatology Life Quality Index; Psoriasis; Psoriasis Area and Severity Index; Rule of Tens; Severity

Indexed keywords

CYCLOSPORIN;

ADULT; BODY SURFACE; DESQUAMATION; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; SKIN INFILTRATE; SYMPTOMATOLOGY; SYSTEMIC THERAPY; TREATMENT INDICATION;

BODY SURFACE AREA; HUMANS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 18944404879     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06502.x     Document Type: Review

References (63)

1. Baughman RD, Sobel R. Psoriasis-a measure of severity. Arch Dermatol 1970; 101:390-5.
2. McKenna KE, Stern RS. The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol 1996; 34:534-8.
3. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141:185-91.
4. Krueger GG, Feldman SR, Camisa C et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43:281-5.
5. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatol Treat 2003; 14:158-65.
6. Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatol Treat 2004; 15:27-9.
7. Finlay AY. Psoriasis from the patient's point of view. Arch Dermatol 2001; 137:352-3.
8. Krueger GG, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 58:280-4.
9. Hermansen SE, Helland CA, Finlay AY. Patients' and doctors' assessment of skin disease handicap. Clin Exp Dermatol 2002; 27:249-50.
10. Sterry W, Barker J, Boehncke W-H et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151 (Suppl. 69): 3-17.
11. Stern RS, Nijsten T, Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004; 9:136-9.
12. Report on the Enquiry into the Impact of Skin Diseases on People's Lives. London: All Party Parliamentary Group on Skin, London, 2003.
13. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41:401-7.
14. Salek MS, Finlay AY. Quality of life in patients with severe psoriasis receiving cyclosporin: a multi-centre study. J Appl Ther Res 2003; 4:3-10.
15. Lewis VL, Finlay AY. Ten years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004; 9:169-80.
16. Faust HB, Gonin R, Chuang TY et al. Reliability testing of the Dermatology Index of Disease Severity (DIDS). An instrument for staging the severity of cutaneous inflammatory disease. Arch Dermatol 1997; 133:1443-8.
17. Fredricksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
18. Feldman SR, Fleischer AB, Reboussin DM et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996; 106:183-6.
19. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-16.
20. Kirby B, Fortune DG, Bhushan M et al. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 2000; 142:728-32.
21. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51:563-9.
22. Shikiar R, Bresnahan BW, Stone SP et al. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1:53.
23. Jose RM, Roy DK, Vidyadharan R, Erdmann M. Burns area estimation-an error perpetuated. Burns 2004; 30:481-2.
24. Long CC, Finlay AY, Averill RW. The Rule of Hand: 4 hand areas = 2 FTU = 1 g. Arch Dermatol 1992; 128:11-30.
25. Rossiter ND, Chapman P, Haywood IA. How big is a hand? Burns 1996; 22:230-1.
26. Nagel TR, Schunk JE. Using the hand to estimate the surface area of a burn in children. Pediatr Emerg Care 1997; 13:254-5.
27. Marks R, Barton SP, Shuttleworth D, Finlay AY. Assessment of disease progress in psoriasis. Arch Dermatol 1989; 125:235-40.
28. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991; 124:565-70.
29. van de Kerkhof PC. On the limitations of the Psoriasis Area and Severity Index (PASI). Br J Dermatol 1992; 126:205 (Letter).
30. Exum ML, Rapp SR, Feldman SR et al. Measuring severity of psoriasis: methodological issues. J Dermatol Treat 1996; 7:119-24.
31. Finlay AY, Gibson SLM. Error in the original description of the Psoriasis Area and Severity Index. Br J Dermatol 1998; 139:53.
32. Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol 2004; 151:381-7.
33. Harari M, Shani J, Hristakieva E et al. Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead Sea. Int J Dermatol 2000; 39:913-18.
34. Zachariae R, Zachariae H, Blomqvist K et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002; 146:1006-16.
35. Carlin CS, Feldman SR, Kreuger JG et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50:859-66.
36. Park SY, Ha SH, Yu DS et al. Quantitative evaluation of severity in psoriatic lesions using three-dimensional morphometry. Exp Dermatol 2004; 13:223-8.
37. Ormerod AD, Dwyer CM, Weller R et al. A comparison of subjective and objective measures of reduction of psoriasis with the use of ultrasound, reflectance colorimetry, computerized video image analysis, and nitric oxide production. J Am Acad Dermatol 1997; 37:51-7.
38. Sampogna F, Gisondi P, Melchi CF et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151:594-9.
39. Heydendael VM, de Borgie CA, Spuls PI et al. The burden of psoriasis is not determined by disease severity only. J Invest Dermatol Symp Proc 2004; 9:131-5.
40. Kirby B, Richards HL, Woo P et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45:72-6.
41. Sampogna F, Sera F, Abeni D et al. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004; 122:602-7.
42. De Korte J, Sprangers MAG, Mombers FMC, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Invest Dermatol Symp Proc 2004; 9:140-7.
43. Finlay AY, Kelly SE. Psoriasis-an index of disability. Clin Exp Dermatol 1987; 12:8-11.
44. Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol (Stockh) 1995; 75:240-3.
45. Chren M-M, Lasek RJ, Quinn LM et al. Skindex, a quality of life measure for patients with skin disease: reliability, validity and responsiveness. J Invest Dermatol 1996; 107:707-13.
46. Nichol MB, Margolies JE, Lippa E et al. The application of multiple quality-of-life instruments in individuals with mild-to-rnoderate psoriasis. Pharmacoeconomics 1996; 10:644-53.
47. Bergstrom KG, Aramulba K, Kimball AB. Medication formulation affects QoL; randomised single-blind study of clobetasol propionate foam 0.05% compared with a combined program of dobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003; 72:407-11.
48. Lewis VJ, Finlay AY. Two decades' experience of the Psoriasis Disability Index. Br J Dermatol 2004; 151 (Suppl. 68): 50-1.
49. McKenna SP, Cook SA, Whalley D et al. Development of the PSO-RIQoL, a psoriasis-specific measure of quality of life developed for use in clinical practice and trials. Br J Dermatol 2003; 149:323-31.
50. Koo J, Menter A, Lebwohl M et al. The relationship between quality of life and disease severity: results from a large cohort of mild, moderate and severe psoriasis patients. Br J Dermatol 2002; 147:1070-1.
51. http://www.dlqi.com (Accessed 21 July 2004).
52. Mazzotti E, Picardi A, Sampogna F et al. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003; 149:318-22.
53. Kimball AB, Krueger GG, Woolley JM. The Dermatology Life Quality Index (DLQI) provides qualitatively different information from the PASI. J Am Acad Dermatol 2004; 50:P156.
54. Ayyalaraju RS, Finlay AY, Dykes PJ et al. Hospitalisation for severe skin disease improves quality of life in the United Kingdom and the United States: a comparative study. J Am Acad Dermatol 2003; 49:249-54.
55. Katugampola RP, Hongbo Y, Finlay AY. The relationship between patient-rated quality of life and clinicians' management decisions in psoriasis-a prospective study. J Invest Dermatol 2004; 123:A70.
56. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004; 150:317-26.
57. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-22.
58. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002; 147 (Suppl. 62): 50 (Abstr.).
59. Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? Br J Dermatol 2004; 151 (Suppl. 68): 45-6.
60. Callen JP, Krueger GG, Lebwohl M et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003; 49:897-9.
61. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132:236-44.
62. Schiffner R, Schiffner-Rohe J, Gerstenhauer M et al. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol 2003; 148:1153-60.
63. Zug KA, Littenberg B, Baughman RD et al. Assessing the preferences of patients with psoriasis. Arch Dermatol 1995; 131:561-8.